Recon: EU regulators investigating Ozempic, Saxenda after reports of possible suicide risk; BeiGene invests in solid tumor ADCs in $1.3B licensing deal
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy